scholarly journals Quantitative evaluation of hepatic steatosis using novel ultrasound technology normalized local variance (NLV) and its standard deviation with different ROIs in patients with metabolic-associated fatty liver disease: a pilot study

2021 ◽  
Author(s):  
Yanan Zhao ◽  
Chao Zhang ◽  
Shaoyan Xu ◽  
Hui Zhang ◽  
Shumei Wei ◽  
...  
Keyword(s):  
Liver Disease ◽  
Standard Deviation ◽  
Liver Biopsy ◽  
Fatty Liver ◽  
Hepatic Steatosis ◽  
Correlation Coefficient ◽  
Fatty Liver Disease ◽  
Diagnostic Performance ◽  
Local Variance ◽  
Ultrasound Technology

Abstract Purpose The purpose of this study was to evaluate the diagnostic performance of novel ultrasound technology normalized local variance (NLV) and the standard deviation of NLV (NLV-SD) using different ROIs for hepatic steatosis in patients with metabolic-associated fatty liver disease (MAFLD) and to identify the factors that influence the NLV value and NLV-SD value, using pathology results as the gold standard. Methods We prospectively enrolled 34 consecutive patients with suspected MAFLD who underwent percutaneous liver biopsy for evaluation of hepatic steatosis from June 2020 to December 2020. All patients underwent ultrasound and NLV examinations. NLV values and NLV-SD values were measured using different ROIs just before the liver biopsy procedure. Results The distribution of hepatic steatosis grade on histopathology was 4/19/6/5 for none (< 5%)/ mild (5–33%)/ moderate (> 33–66%)/ and severe steatosis (> 66%), respectively. The NLV value with 50-mm-diameter ROI and NLV-SD value with 50-mm-diameter ROI showed a significant negative correlation with hepatic steatosis (spearman correlation coefficient: − 0.449, p = 0.008; − 0.471, p = 0.005). The AUROC of NLV (50 mm) for the detection of mild, moderate, and severe hepatic steatosis was 0.875, 0.735, and 0.583, respectively. The AUROC of NLV-SD (50 mm) for the detection of mild, moderate, and severe hepatic steatosis was 0.900, 0.745, and 0.603, respectively. NLV (50 mm) values and NLV-SD (50 mm) values between two readers showed excellent repeatability and the intraclass correlation coefficient (ICC) was 0.930 (p < 0.001) and 0.899 (p < 0.001). Hepatic steatosis was the only determinant factor for NLV value and NLV-SD value (p = 0.012, p = 0.038). Conclusion The NLV (50 mm) and NLV-SD (50 mm) provided good diagnostic performance in detecting the varying degrees of hepatic steatosis with great reproducibility. This study showed that the degree of steatosis was the only significant factor affecting the NLV value and NLV-SD value.

scholarly journals Association Between Hepatic Steatosis and Metabolic Syndrome in Patients With Non-alcoholic Fatty Liver Disease

2021 ◽  
Vol 5 (Supplement_2) ◽  
pp. 858-858
Author(s):  
Victoria Quadros Pereira ◽  
Carine Panke ◽  
Leticia Eifler ◽  
Cristiane Tovo ◽  
Thaís Moreira
Keyword(s):  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Liver Disease ◽  
Liver Biopsy ◽  
Fatty Liver ◽  
Hepatic Steatosis ◽  
Fatty Liver Disease ◽  
Serum Triglycerides ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Abstract Objectives Evaluate the association between the degree of hepatic steatosis and the development of metabolic syndrome in outpatients care. Methods Prospective cross-sectional study with outpatients care at the Gastroenterology Service of a hospital in southern Brazil. The study was approved by the Ethics Committee with protocol 57,328,416.8.0000.5335. Patients aged over 18 years and with non-alcoholic fatty liver disease were included. Patients were excluded from hepatitis B and C, with significant alcohol consumption and hepatocellular carcinoma. Data collection occurred during nutritional consultations, where we collected data of age, gender, lifestyle, diagnosis of comorbidities and biochemical tests. The result of liver biopsy was evaluated for the degree of hepatic steatosis. Anthropometric parameters were assessed for the diagnosis of metabolic syndrome, in addition to electrical bioimpedance for body composition. Data were presented as mean, median, standard deviation, interquartile range and percentages according to distribution. Student T, ANOVA and Pearson correlation tests were applied. The significance level was 5%. Results We evaluated 71 patients with mean age 59.08 ± 8.92 years, 67.6% (n = 48) women, 60.6% (n = 43) sedentary, 52.2% (n = 37) no smoking and mean body mass index of 32.91 ± 5.27 kg/m2. Systemic arterial hypertension were diagnosed in 80.3% (n = 57), 73.2% (n = 52) were diabetic, 66.2% (n = 47) were dyslipidemic and 28.2% (n = 20) of patients with metabolic syndrome. As liver biopsy, 25.4% (n = 18) mild steatosis, 23.9% (n = 17) moderate and 26.8% (n = 19) intense. In the comparison between the levels of hepatic steatosis and the variables, it was observed that patients with severe steatosis had metabolic syndrome (p = 0.041). Patients with metabolic syndrome have higher fat mass (p = 0.044), diastolic blood pressure (p = 0.019) and higher levels of serum triglycerides (p = 0.043). Severe hepatic steatosis correlated with the diagnosis of metabolic syndrome (r = 0.319; p = 0.019). Conclusions Severe hepatic steatosis is related to the diagnosis of metabolic syndrome.Patients with metabolic syndrome had a higher amount of fat mass, increased diastolic blood pressure and serum triglycerides. Funding Sources This study was not funded.

The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease

2020 ◽  
Vol 26 (32) ◽  
pp. 3928-3938
Author(s):  
Grazia Pennisi ◽  
Ciro Celsa ◽  
Antonina Giammanco ◽  
Federica Spatola ◽  
Salvatore Petta
Keyword(s):  
Liver Disease ◽  
Liver Biopsy ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Assessment Tools ◽  
Hepatic Decompensation ◽  
Alcoholic Fatty Liver ◽  
Simple Steatosis ◽  
Life Threatening ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver diseases worldwide, involving about 25% of people. NAFLD incorporates a large spectrum of pathological conditions, from simple steatosis to non-alcoholic steatohepatitis (NASH), cirrhosis and its complications include hepatic decompensation and hepatocellular carcinoma (HCC). This progression occurs, over many years, in an asymptomatic way, until advanced fibrosis appears. Thus, the differentiation of NASH from simple steatosis and identification of advanced hepatic fibrosis are key issues. To date, the histological assessment of fibrosis with liver biopsy is the gold standard, but obviously, invasiveness is the greater threshold. In addition, rare but potentially life-threatening complications, poor acceptability, sampling variability and cost maybe restrict its use. Furthermore, due to the epidemic of NAFLD worldwide and several limitations of liver biopsy evaluation, noninvasive assessment tools to detect fibrosis in NAFLD patients are needed.

Sign in / Sign up

Export Citation Format

Share Document